The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zaytseva O.V.

Helmholtz National Medical Research Center of Eye Diseases;
A.I. Evdokimov Moscow State University of Medicine and Dentistry

Neroeva N.V.

Helmholtz National Medical Research Center of Eye Diseases

Okhotsimskaya T.D.

Helmholtz National Medical Research Center of Eye Diseases

Bobykin E.V.

Ural State Medical University

Anti-VEGF therapy for neovascular age-related macular degeneration: causes of incomplete response

Authors:

Zaytseva O.V., Neroeva N.V., Okhotsimskaya T.D., Bobykin E.V.

More about the authors

Journal: Russian Annals of Ophthalmology. 2021;137(5): 152‑159

DOI: 10.17116/oftalma2021137051152

Read: 3026 times

Download PDF (RU)
Contact the author
Table of contents

ANTI-VEGF THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: CAUSES OF INCOMPLETE RESPONSE
ANTI-VEGF THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: CAUSES OF INCOMPLETE RESPONSE

To cite this article:

Zaytseva OV, Neroeva NV, Okhotsimskaya TD, Bobykin EV. Anti-VEGF therapy for neovascular age-related macular degeneration: causes of incomplete response. Russian Annals of Ophthalmology. 2021;137(5):152‑159. (In Russ.)
https://doi.org/10.17116/oftalma2021137051152

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Effi­cacy of brolucizumab in the treatment of reti­nal pathologies: a review of post-marketing studies. Russian Annals of Ophthalmology. 2024;(5):154-161
Analysis of the effe­ctiveness of cata­ract surgery in neovascular age-related macu­lar dege­neration. Russian Annals of Ophthalmology. 2024;(6):7-14
Mana­gement of patients with treatment-resistant neovascular age-related macu­lar dege­neration. Russian Annals of Ophthalmology. 2024;(6):63-68
Glucocorticoid-resistant forms of endo­crine ophthalmopathy. Russian Annals of Ophthalmology. 2024;(6):125-130
Neuroprotective therapy for age-related macu­lar dege­neration. Russian Annals of Ophthalmology. 2024;(6):152-158
Asso­ciation between inte­grity of foveal photoreceptors and ulti­mate visual outcome in neovascular age-related macu­lar dege­neration. Russian Annals of Ophthalmology. 2025;(1):32-36
Choroidal neovascularization asso­ciated with choroidal nevi. Russian Annals of Ophthalmology. 2025;(1):104-112
Arti­ficial inte­lligence in asse­ssment of indi­vidual risks of age-related macu­lar dege­neration progression. Russian Annals of Ophthalmology. 2025;(2):123-128
Clinical and psychopathological features of treatment-resistant schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):43-50
Genome instability of the cholera agent: role in the evolution of pathogenicity, drug resi­stance and adaptation to a changing envi­ronment. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(2):3-13
Abstract:

Neovascular age-related macular degeneration (nAMD) is one of the leading causes of decreased vision in the elderly population in many countries, including Russia. Anti-VEGF therapy is undoubtedly the «gold standard» of treatment for the disease, but its use in different patients is known to produce results with significant interindividual differences. This article reviews modern ideas about the clinical assessment of the degree of response to anti-VEGF therapy, possible reasons for its insufficient effectiveness (clinical, pharmacological, or related to nAMD pathogenesis), discusses the potential applications of the existing therapeutic strategies, and considers the prospects for the emergence of new strategies that could be used for solving that problem.

Keywords:

age-related macular degeneration
anti-VEGF therapy
macular neovascularization
resistance
incomplete response

Authors:

Zaytseva O.V.

Helmholtz National Medical Research Center of Eye Diseases;
A.I. Evdokimov Moscow State University of Medicine and Dentistry

Neroeva N.V.

Helmholtz National Medical Research Center of Eye Diseases

Okhotsimskaya T.D.

Helmholtz National Medical Research Center of Eye Diseases

Bobykin E.V.

Ural State Medical University

Received:

09.07.2021

Accepted:

09.09.2021

Close metadata

References:

  1. Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392:1147-1159. https://doi.org/10.1016/S0140-6736(18)31550-2
  2. Chhablani J, ed. Choroidal Neovascularization. Singapore: Springer; 2020. https://doi.org/10.1007/978-981-15-2213-0_21#DOI
  3. Burton MJ, Ramke J, Marques AP, Bourne RRA, Congdon N, et al. The Lancet Global Health Commission on Global Eye Health: vision beyond 2020. Lancet Glob Health. 2021;9(4):489-551.  https://doi.org/10.1016/S2214-109X(20)30488-5
  4. Ivakhnenko OI, Neroyev VV, Zaytseva OV. Age-related macular degeneration and diabetic eye lesion. Socio-economic aspects. Vestnik oftal’mologii. 2021;137(1):123-129 (In Russ.). https://doi.org/10.17116/oftalma2021137011123
  5. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):106-116.  https://doi.org/10.1016/S2214-109X(13)70145-1
  6. Li JQ, Welchowski T, Schmid M, Mauschitz MM, Holz FG, Finger RP. Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis. Br J Ophthalmol. 2020;104(8): 1077-1084. https://doi.org/10.1136/bjophthalmol-2019-314422
  7. Farinha C, Silva R. Neovascular AMD: Clinical Features and Imaging. In: Chhablani J, ed. Choroidal Neovascularization. Singapore: Springer; 2020; 73-98.  https://doi.org/10.1007/978-981-15-2213-0_7
  8. Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, et al. Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology. 2020;127(5):616-636.  https://doi.org/10.1016/j.ophtha.2019.11.004
  9. Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2019;3(3):CD005139. https://doi.org/10.1002/14651858.CD005139.pub4
  10. Ruamviboonsuk P, Chotcomwonse P, Nganthavee V, Pattanapongpaiboon W, Hemarat K. Clinical Trials Related to Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. In: Chhablani J., eds. Choroidal Neovascularization. Singapore: Springer; 2020;259-282.  https://doi.org/10.1007/978-981-15-2213-0_20
  11. Okhotsimskaya TD, Zaitseva OV. Aflibercept for the therapy of retinal diseases. A review of clinical studies. Rossiiskii oftal’mologicheskii zhurnal. 2017; 10(2):103-111 (In Russ.). https://doi.org/10.21516/2072-0076-2017-10-2-103-111
  12. Korotkikh SA, Bobykin EV. Our experience in visual functions’ improvement in patiens with «wet» age-related macular degeneration at switching from one anti-VEGF agent to another. Oftal’mologicheskiye vedomosti = Ophthalmology Journal. 2017;10(3):67-73 (In Russ.). https://doi.org/10.17816/OV10367-73
  13. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-1398. https://doi.org/10.1016/j.ophtha.2012.03.053
  14. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U. VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-2548. https://doi.org/10.1016/j.ophtha.2012.09.006
  15. Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, Gedif K, Jaffe GJ, Tadayoni R, Schmidt-Erfurth U, Holz FG. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2021;128(1):89-99.  https://doi.org/10.1016/j.ophtha.2020.06.028
  16. Yang S, Zhao J, Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther. 2016;10:1857-1867. https://doi.org/10.2147/DDDT.S97653
  17. Wykoff CC, Brown DM, Maldonado ME, Croft DE. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol. 2014;98(7):951-955.  https://doi.org/10.1136/bjophthalmol-2013-304736
  18. Amoaku WM, Chakravarthy U, Gale R, Gavin M, Ghanchi F, Gibson J, Harding S, Johnston RL, Kelly SP, Lotery A, Mahmood S, Menon G, Sivaprasad S, Talks J, Tufail A, Yang Y. Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond). 2015;29(6):721-731.  https://doi.org/10.1038/eye.2015.48
  19. Van Asten F, Rovers MM, Lechanteur YT, Smailhodzic D, Muether PS, Chen J, den Hollander AI, Fauser S, Hoyng CB, van der Wilt GJ, Klevering BJ. Predicting non-response to ranibizumab in patients with neovascular age-related macular degeneration. Ophthalmic Epidemiol. 2014;21(6):347-355.  https://doi.org/10.3109/09286586.2014.949010.
  20. Yazdi MH, Faramarzi MA, Nikfar S, Falavarjani KG, Abdollahi M. Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration. Expert Opin Biol Ther. 2015;15(9):1349-1358. https://doi.org/10.1517/14712598.2015.1057565.
  21. Li H, Lei N, Zhang M, Li Y, Xiao H, Hao X. Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit. Exp Eye Res. 2012;97(1):154-159.  https://doi.org/10.1016/j.exer.2011.09.002
  22. Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol. 2012;96(1):1-2.  https://doi.org/10.1136/bjophthalmol-2011-301236
  23. Arjamaa O, Minn H. Resistance, not tachyphylaxis or tolerance. Br J Ophthalmol. 2012;96(8):1153-1154. https://doi.org/10.1136/bjophthalmol-2012-301823
  24. Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina. 2009;29(6):723-731.  https://doi.org/10.1097/IAE.0b013e3181a2c1c3
  25. Eghøj MS, Sørensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2012; 96(1):21-23.  https://doi.org/10.1136/bjo.2011.203893.
  26. Broadhead GK, Hong T, Chang AA. Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration. Acta Ophthalmol. 2014;92(8):713-723.  https://doi.org/10.1111/aos.12463
  27. Gharbiya M, Iannetti L, Parisi F, De Vico U, Mungo ML, Marenco M. Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Biomed Res Int. 2014; 2014:273754. https://doi.org/10.1155/2014/273754
  28. Chang AA, Li H, Broadhead GK, Hong T, Schlub TE, Wijeyakumar W, Zhu M. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology. 2014;121(1):188-192.  https://doi.org/10.1016/j.ophtha.2013.08.035
  29. Hamid MA, Abdelfattah NS, Salamzadeh J, Abdelaziz STA, Sabry AM, Mourad KM, Shehab AA, Kuppermann BD. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Int J Retina Vitreous. 2021;7(1):26.  https://doi.org/10.1186/s40942-021-00299-4
  30. Arcinue CA, Ma F, Barteselli G, Sharpsten L, Gomez ML, Freeman WR. One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration. Am J Ophthalmol. 2015;159(3):426-436.e2.  https://doi.org/10.1016/j.ajo.2014.11.022
  31. Moon DRC, Lee DK, Kim SH, You YS, Kwon OW. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor. Korean J Ophthalmol. 2015;29(4):226-232.  https://doi.org/10.3341/kjo.2015.29.4.226
  32. Tranos P, Vacalis A, Asteriadis S, Koukoula S, Vachtsevanos A, Perganta G, Georgalas I. Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration. Drug Des Devel Ther. 2013;7:485-490.  https://doi.org/10.2147/DDDT.S43470
  33. Razavi S, Kodjikian L, Giocanti-Aurégan A, Dufour I, Souied E. Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration. BMC Ophthalmol. 2021; 21(1):90.  https://doi.org/10.1186/s12886-021-01841-6
  34. Yonekawa Y, Andreoli C, Miller JB, Loewenstein JI, Sobrin L, Eliott D, Vavvas DG, Miller JW, Kim IK. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol. 2013;156(1):29-35.e2.  https://doi.org/10.1016/j.ajo.2013.03.030
  35. Shin JY, Woo SJ, Ahn J, Park KH. Anti-VEGF-refractory exudative age-related macular degeneration: differential response according to features on optical coherence tomography. Korean J Ophthalmol. 2013;27(6):425-432.  https://doi.org/10.3341/kjo.2013.27.6.425
  36. Brown DM, Chen E, Mariani A, Major JC Jr. SAVE Study Group. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. Ophthalmology. 2013;120(2):349-354.  https://doi.org/10.1016/j.ophtha.2012.08.008
  37. Grewal DS, Gill MK, Sarezky D, Lyon AT, Mirza RG. Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results. Eye (Lond). 2014;28(7):895-899.  https://doi.org/10.1038/eye.2014.101
  38. Puliafito CA. Recalcitrant neovascular macular degeneration after anti-VEGF therapy: an ongoing challenge. Ophthalmic Surg Lasers Imaging Retina. 2013; 44(2):109.  https://doi.org/10.3928/23258160-20130313-01
  39. Kanesa-Thasan A, Grewal DS, Gill MK, Lyon AT, Mirza RG. Quantification of Change in Pigment Epithelial Detachment Volume and Morphology After Transition to Intravitreal Aflibercept in Eyes With Recalcitrant Neovascular AMD: 18-Month Results. Ophthalmic Surg Lasers Imaging Retina. 2015;46(6):638-641.  https://doi.org/10.3928/23258160-20150610-07
  40. Kuroda Y, Yamashiro K, Miyake M, Yoshikawa M, Nakanishi H, Oishi A, Tamura H, Ooto S, Tsujikawa A, Yoshimura N. Factors Associated with Recurrence of Age-Related Macular Degeneration after Anti-Vascular Endothelial Growth Factor Treatment: A Retrospective Cohort Study. Ophthalmology. 2015;122(11):2303-2310. https://doi.org/10.1016/j.ophtha.2015.06.053
  41. Joondeph BC. Anti-vascular endothelial growth factor injection technique for recurrent exudative macular degeneration in a telescope-implanted eye. Retin Cases Brief Rep. 2014;8(4):342-344.  https://doi.org/10.1097/ICB.0000000000000065
  42. Rezar-Dreindl S, Sacu S, Eibenberger K, Pollreisz A, Bühl W, Georgopoulos M, Krall C, Weigert G, Schmidt-Erfurth U. The Intraocular Cytokine Profile and Therapeutic Response in Persistent Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2016;57(10):4144-4150. https://doi.org/10.1167/iovs.16-19772
  43. Wang Z, Li M, Yao Y, Hu J, Tang J, Tang R, Piao Z, Qu J. Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration. J Ophthalmol. 2020;2020:9340356. https://doi.org/10.1155/2020/9340356
  44. Ying GS, Maguire MG, Daniel E, Ferris FL, Jaffe GJ, Grunwald JE, Toth CA, Huang J, Martin DF. Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology. 2015; 122(12):2523-2531.e1.  https://doi.org/10.1016/j.ophtha.2015.08.015
  45. Li J, Xu J, Chen Y, Zhang J, Cao Y, Lu P. Efficacy Comparison of Intravitreal Anti-VEGF Therapy for Three Subtypes of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis. Journal of Ophthalmology. 2018;1425707:10p.  https://doi.org/10.1155/2018/1425707
  46. Sadda SR, Tuomi LL, Ding B, Fung AE, Hopkins JJ. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2018;125(6):878-886.  https://doi.org/10.1016/j.ophtha.2017.12.026
  47. Framme C, Eter N, Hamacher T, Hasanbasic Z, Jochmann C, Johnson KT, Kahl M, Sachs H, Schilling H, Thelen U, Wiedemann P, Wachtlin J. Prospective Noninterventional Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients with Neovascular Age-Related Macular Degeneration Study Group. Aflibercept for Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in Germany: Twelve-Month Outcomes of PERSEUS. Ophthalmol Retina. 2018; 2(6):539-549.  https://doi.org/10.1016/j.oret.2017.09.017
  48. Ebneter A, Michels S, Pruente C, Imesch P, Eilenberger F, Oesch S, Thomet-Hunziker IP, Hatz K. Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration. Sci Rep. 2020;10:20256. https://doi.org/10.1038/s41598-020-76354-1
  49. Jhaveri CD, et al. Presentation at the 37th Annual Meeting of the American Society of Retina Specialists (ASRS); Chicago, IL, USA, July 26—31, 2019.
  50. Arnold JJ, Markey CM, Kurstjens NP, Guymer RH. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration — a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmol. 2016;16:31.  https://doi.org/10.1186/s12886-016-0207-3
  51. Ohji M, et al. Relationship between retinal fluid and functional outcomes in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: post-hoc analysis of the ALTAIR study. Abstract and presentation at Euretina 2020, Free paper session (AMD).
  52. Dugel PU et al. Presentation at the 13th Congress of the Asia-Pacific Vitreo-retina Society (APVRS); Shanghai, China, November 22—24, 2019.
  53. Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res. 2016; 50:1-24.  https://doi.org/10.1016/j.preteyeres.2015.07.007
  54. Jaffe GJ, Ying GS, Toth CA, Daniel E, Grunwald JE, Martin DF, Maguire MG. Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology. 2019;126(2):252-260.  https://doi.org/10.1016/j.ophtha.2018.08.035
  55. Westfall TC, Westfall DP. Goodman and Gilman’s. The Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill; 2011.
  56. Bunnel CA. Intensive Review of Internal Medicine. Boston, MA: Harvard Medical School; 2009.
  57. Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z, Rubio RG, Lai P; HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046-1056. https://doi.org/10.1016/j.ophtha.2012.10.014
  58. Wu E, Palmer N, Tian Z, Moseman AP, Galdzicki M, Wang X, Berger B, Zhang H, Kohane IS. Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells. PLoS One. 2008;3(11): e3794. https://doi.org/10.1371/journal.pone.0003794
  59. Rusnati M, Presta M. Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Curr Pharm Des. 2007;13(20):2025-2044. https://doi.org/10.2174/138161207781039689
  60. Dunn EN, Hariprasad SM, Sheth VS. An Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications. Ophthalmic Surg Lasers Imaging Retina. 2017;48(2):100-104.  https://doi.org/10.3928/23258160-20170130-02
  61. Bobykin EV. Treatment of macular diseases: a look into the future (literature review). Otrazhenie. 2020;1-2(10):61-72. (In Russ.). https://doi.org/10.25276/2686-6986-2020-1-61-72
  62. Weber BH, Charbel Issa P, Pauly D, Herrmann P, Grassmann F, Holz FG. The role of the complement system in age-related macular degeneration. Dtsch Arztebl Int. 2014;111(8):133-138.  https://doi.org/10.3238/arztebl.2014.0133
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.